Company Profile

  1. You are here:    Home
  2. Search Databases
  3. Search Company Registry
  4. Company Profile

Trace-Ability Inc
Profile last edited on: 6/7/2018      CAGE: 6YCC3      UEI: S11KA2DGF4J6

Business Identifier: Radio-pharmaceutical quality control
Year Founded
2013
First Award
2015
Latest Award
2022
Program Status
Active
Popularity Index

Edit Company Profile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
  Explanation Edit

Location Information

2446 20th Street
Santa Monica, CA 90405
   (310) 988-0463
   N/A
   www.traceabilityinc.com
Location: Single
Congr. District: 33
County: Los Angeles

Public Profile

Traceability Inc. has developed a series of radio-pharmaceutical quality control tests that can be run on a single plate reader in combination with an innovative consumable kit. The company's Tracer-QC™ system is based on assays that yield optical signals that are measured by the plate reader and compiled into a report on compliance with all relevant QC standards using Trace-Ability's 21 CFR Part 11-compliant software. Through a distribution partnership with LabLogic Systems Inc., the company offers instruments, kits, training, service and support.

Extent of SBIR involvement

User Avatar
Phase I Awards
7
Phase II Awards
5
Conversion Rate
71.43%
Phase I Dollars
$2,436,726
Phase II Dollars
$6,659,477
Total Awarded
$9,096,203

Synopsis: Awardee Business Condition

Employee Range
5-9
Revenue Range
.5M-1M
VC funded?
No
Public/Private
Privately Held
Stock Info
----
IP Holdings
1-4

Awards Distribution by Agency

Most Recent SBIR Projects
Year Phase Agency Total Amount
2024 2 NIH $1,299,987
Project Title: Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based cancer imaging PET tracers on a single platform
2023 2 NIH $2,364,558
Project Title: Analytical Methods for Automated Quality Control of Cancer Pet Imaging Tracer - [F-18]FDG
2022 2 NIH $2,508,450
Project Title: Enabling nationwide AD PET imaging to support most efficient clinical trials by adoption of radically simplified and standardized quality control in commercial production of AD PET tracers.
2021 1 NIH $168,087
Project Title: Rapid pre-release sterility test for PET Drugs.
2020 2 NIH $1,732,934
Project Title: Development of Completely Automated Quality Control Procedures for 4 PET Imaging Tracers That Will Increase Production Throughput and Lead to Expanded Diversity of PET Imaging Available to Patients

Key People / Management

  Arkadij Elizarov -- CEO

  Artem Lebedev -- CTO

Company News

There are no news available.